A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis

Trial Profile

A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 29 May 2018

At a glance

  • Drugs Arimoclomol (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Sponsors Orphazyme
  • Most Recent Events

    • 29 May 2018 According to the Orphazyme media release, interim analysis is expected at 70% completion in H2 2020 and full analysis in H1 2021.
    • 06 Apr 2018 Status changed from planning to not yet recruiting.
    • 25 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top